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Edited by Hans-Dieter KlenkAbstract In certain cell systems, exchange of the human immu-
nodeﬁciency virus (HIV) Env signal peptide (SP) sequence with
that of heterologous SPs has been shown to increase gp120
transport and secretion. Here we demonstrate that exchange of
the HIV-Env-SP with those from erythropoietin or tissue plas-
minogen activator in the proviral context does not increase
wild-type membrane-bound Env expression or incorporation into
released virions. In fact, virion infectivities were decreased.
These infectivity decreases were largely due to eﬀects on Env
transport and/or function and only to a minor extent to cis eﬀects
as a result of the sequence exchanges themselves. Thus, in fact, it
is not advantageous to employ heterologous SPs to achieve high-
level expression of functional cell surface membrane- or virion-
associated HIV-Env.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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In common with many other integral membrane or secreted
proteins, the HIV-1-Env glycoprotein contains an N-terminal
signal peptide (SP) sequence which directs the nascent poly-
peptide to the endoplasmatic reticulum (ER). The 30 amino
acid (aa) HIV-Env-SP is rather long and consists of a polar
N-terminal region followed by a hydrophobic core [1]. In con-
trast to the cleavage of the SPs of many other glycoproteins,
cleavage of the HIV-Env-SP in several cell lines is post-trans-
lational and very slow [2–4]. The HIV-SP associates with caln-
exin in the ER and this association has been implicated to
down-modulate glycoprotein folding [3,4]. In fact, there ap-
pears to be a mutual relationship between SP removal and
gp160 folding. Thus lack of SP removal delays or disturbs
HIV-Env folding while, on the other hand, Env folding is re-
quired for SP removal [3–5].
Generally, expression and intracellular transport of mature
gp120 and gp41 in mammalian cells is ineﬃcient and only a
small fraction (5–15%) of gp160 synthesised within the cell is
processed to gp120 and gp41 and incorporated into released
virions [6]. In early studies aimed at achieving eﬃcient HIV-
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cells [2,9]. In S. frugiperda (SF9) insect cells, expression of se-
creted gp120 from recombinant baculovirus was signiﬁcantly
increased by replacement of the Env-SP with the SPs from mel-
ittin or from murine interleukin 3 or by elimination of posi-
tively charged aa within the Env-SP itself [2]. Also in
mammalian cells, replacement of the HIV-Env-SP with heter-
ologous SPs (from erythropoietin (Epo) and from tissue plas-
minogen activator (tPA)) has been reported to increase
gp120 secretion, albeit not to such a pronounced extent as in
insect cells [10]. In fact, the use of heterologous SPs to poten-
tially increase HIV-Env secretion is a strategy which is still
wide-spread [11].
In vaccine strategies based on inactivated virions, virus-like
particles or liposomes, high-level expression of membrane-
anchored Env, generally in a functional form, has to be
achieved. In this report, we have analysed if heterologous
SPs would potentially be beneﬁcial in these situations. We have
generated proviral constructs encoding Env protein chimeras
with SPs from either erythropoietin (this SP carries includes
only a single charged aa) or tPA (this SP carries several
charged aa) and compared the properties of these glycopro-
teins and of the respective mutant virions to those of their
wild-type counterparts.2. Materials and methods
2.1. Constructs
Proviral plasmids were based on pNL4-3BH10 env (referred to here
as pNL-Wt) [12]. Vpu expression was abolished by mutating the
vpu initiation codon to ATT (exchanging G at nucleotide position
6063 (all numbering from pNL4-3 [13]) to T). The heterologous
SPs employed to replace the HIV-Env-SP (Env aa 1–30 encoded by
ATGAGAGTGAAGGAGAAATATCAGCACTTGTGGAGATGG-
GGGTGGAGATGGGGCACCATGCTCCTTGGGATGTTGAT-
GATCTGTAGTGCT, nucleotides 6221–6310) were either from
erythropoietin (Epo-SP) (aa 1–26, numbering starting at the initiation
methionine, encoded by the sequence ATGGGGGTGCACGAAT-
GTCCTGCCTGGCTGTGGCTTCTCCTGTCCCTGCTGTCGCT-
CCCTCTGGGCCTCCCAGTCCTG) or from tissue plasminogen
activator (tPA-SP) (aa 1–35, numbering starting at the initiation
methionine, encoded by the sequence ATGGATGCAATGAAGA-
GAGGGCTCTGCTGTGTGCTGCTGCTGTGTGGAGCAGTCT-
TCGTTTCGCCCAGCCAGGAAATCCATGCCCGATTCAGAA-
GAGGAGCCAGA). For identiﬁcation purposes, in these latter
cases, a SacI site was introduced 15 nucleotides upstream of the
env gene, i.e. in the non-expressed vpu gene, by exchanging AG
(nucleotides 6207, 6208) with TC. SalI–KpnI fragments (nucleotides
5785–6343), containing the exchanges in the Vpu-ATG and Env-SP,
were generated using standard PCR technologies and employed to


































Fig. 1. (A) Schematic representation of the proviral constructs with
Env-SP exchanges. The sequences and charges of the amino acids of
the HIV-Env-SP, the Epo-SP and tPA-SP are given. Expression of Vpu
has been abrogated by mutation of the initiation ATG to ATT. (B)
Western blot analysis of equalised amounts (by ELISA for CA) of cell
lysates (left) and of lysates of released virions (right) from 293T cells
transfected with the respective proviral constructs as indicated. The
top parts of the ﬁlters have been probed with anti-gp120 and the
bottom parts with anti-p24.
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and revealed an inadvertent nucleotide deletion (A at nucleotide
position 6164) in all cases. This deletion is in the non-expressed vpu
gene, upstream of env, and was not corrected. The resulting plasmids
are designated pNL-Wt (vpu-), pNL-Epo-SP and pNL-tPA-SP.
2.2. Expression of modiﬁed proviruses, cell–cell fusion levels mediated by
mutant Env proteins
Proviral constructs pNL-Wt, pNL-Wt (vpu-), pNL-Epo-SP and
pNL-tPA-SP were transfected into 293T cells employing standard cal-
cium phosphate procedures. In some experiments, virions were
pseudotyped with the glycoprotein of vesicular stomatitis virus
(VSV-G) by cotransfection of the respective proviral plasmids with
pMD.G [14]. Two days post-transfection (p.t.), the culture superna-
tants were ﬁltered (0.45 lm ﬁlter) and, for Western blot analysis, re-
leased virions were concentrated by centrifugation at 200000 · g for
3 h through a cushion of 20% sucrose. Virions in culture supernatants
or after concentration were quantitated by ELISA for HIV-CA (Inno-
genetics, Belgium). Lysates of transfected cells were prepared in 1%
Triton X-100 in phosphate buﬀered saline (PBS). Western blot analy-
ses of cell lysates (equalised by CA-ELISA of the respective culture
supernatants) and of viral lysates (equivalent to 100 ng CA) were
performed employing rabbit anti-gp120 antibodies and anti-p24 Mab
183-H12-5C [15].
A semi-quantitative assay to assess cell–cell fusion activities was per-
formed essentially as previously described [16]. Brieﬂy, 293T cells
growing in 6-well dishes were transfected with the respective proviral
constructs and cultivated from 5 to 48 h p.t. in the presence of
1.5 lM HIV protease inhibitor, Saquinivir (Hofmann-La Roche,
Basel, Switzerland), to prevent release of infectious virions. At 48 h
p.t., the cells were overlayed with 3 ml conﬂuent 1G5 cells, which are
Jurkat cells containing a stably integrated HIV-LTR ﬁre-ﬂy luciferase
construct. Cocultivation was continued for 4 h during which time syn-
cytium formation between the two cell types results in activation of
LTR-driven luciferase expression by Tat protein from the transfected
293T cells. The cocultured cells were then lysed and luciferase activities
measured using standard procedures. In order to normalise for possi-
ble diﬀerences in transfection eﬃciencies, parallel transfections were
cultivated in the absence of Saquinivir, the amounts of released virions
reﬂecting the infection eﬃciencies determined by CA-ELISA (these
were generally in the same range) and the measured luciferase values
adjusted accordingly.
2.3. Infectivity assays
Equalised amounts (determined by CA-ELISA) of virions released
from transfected 293T cells were titrated in triplicate on Tzm-bl indi-
cator cells [17–19] in the presence of 1.5 lM Saquinivir (to prevent
spread of infection). In the case of VSV-G pseudotyped virions Tzm-
bl cells were preincubated with, and titrations carried out in the pres-
ence of culture supernatants (1:1) from SIM2 and SIM4 hybridoma
cells which produce antibodies against CD4 [20]. We demonstrated
in a control experiment that this incubation inhibits HIV-Env medi-
ated infectivity by more that 99%. At 36 h p.i., infected cells were
stained for b-galactosidase activity, counted and titer of infectious
units (IU) per millilitre calculated. Spreading infections in H9 T-cells
(106 cells in 3 ml) were initiated with equalised amounts (equivalent
to 100 ng CA ) of the respective virions, generated in transfected
293T cells. Input virus was removed at 5 h p.i. and the cells washed
twice. Aliquots of media were collected at diﬀerent time-points post-
infections and the amounts of newly synthesised released virus quanti-
tated by CA-ELISA.3. Results and discussion
3.1. Expression of proviral constructs encoding Env proteins with
heterologous SPs
The proviral constructs encoding Env proteins with either
Wt-Env-SP, Epo-SP or tPA-SP are illustrated in Fig. 1A.
The SP replacements in Env lead to premature termination
of the Vpu protein. Thus, in order to carry out comparative
analyses, initiation of Vpu translation was completely abol-ished in a control plasmid (pNL-Wt (vpu-)) as well as in both
pNL-Epo-SP and pNL-tPA-SP plasmids by mutating the Vpu
initiation ATG to ATT. Although in many cell lines, abroga-
tion of Vpu expression results in less eﬃcient release of virus
particles into the extracellular medium [21,22], this was not
the case in 293T cells. Thus, levels of virus particle release
(as quantitated by CA ELISA) were equivalent after transfec-
tion with pNL-Wt (intact vpu gene) or with the any of the vpu-
deﬁcient proviruses (data not shown). Fig. 1B shows Western
blot analysis of the respective cell and viral lysates. The total
amounts of expressed viral glycoproteins in the transfected
cells were equivalent (left panel) and incorporation into virions
occurred in all cases (right panel). However, there was no in-
crease in the extent of glycoprotein incorporation in the case
of the proviruses expressing Env proteins with heterologous
SPs. In fact, we reproducibly observed that incorporation
was slightly impaired in the case of pNL-tPA-SP. This means
that in the context of full-length HIV-Env, the tested heterol-
ogous SPs, which include an SP which, in contrast to the
HIV-SP, is only very weakly charged (Epo-SP), do not lead
to an increase in Env expression or particle incorporation lev-
els. Since the extent of incorporation into particles is at least
partially determined by the level of surface expression of retro-
viral glycoproteins [23], these analyses make it unlikely that the
heterologous SPs increase HIV-Env transport to the cell sur-
face. On the contrary, the decreased incorporation of Env
from into pNL-tPA-SP particles would rather point to a dele-
terious eﬀect, perhaps as a result of incomplete SP removal or
to incorrect folding as a result of premature SP removal.
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heterologous SPs
Virions released from 293T cells transfected with pNL-Wt,
pNL-Wt (vpu-), pNL-Epo-SP and pNL-tPA-SP were ﬁrst ana-
lysed in single-round infectivity assays in Tzm-bl reporter cells.
As shown in Fig. 2A, there was no signiﬁcant diﬀerence in the
titers of virions expressed from pNL-Wt or pNL-Wt (vpu-),
i.e. with or without vpu expression. On the other hand, the
infectivities of virions expressed from pNL-Epo-SP or pNL-
tPA-SP proviral plasmids were reduced to levels of about
30% of that of wild-type. We then analysed the eﬀects of the
SP exchanges on the kinetics of viral replication and spread
in T-cells. Fig. 2B shows analysis of the kinetics of infection
in H9 T-cells which had been infected with equal amounts of
the respective virions produced in 293T cells. The kinetics of
spread of pNL-Wt and pNL-Wt (vpu-) virions were approxi-
mately the same indicating that, in this culture system, Vpu
expression did not markedly inﬂuence viral spread. However,
pNL-Epo-SP and, more markedly pNL-tPA-SP virions, both
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Fig. 2. Infectivities of virions released from 293T cells transfected with
the respective proviral constructs. (A) Analysis of ‘‘single-round’’
infectivities by titration on Tzm-bl indicator cells. The titers for pNL-
Wt (which were in the range of 3 · 106 IU/ml) were taken as 100% and
the relative infectivities of the mutant viruses calculated. The average
of 2 experiments is shown. (B) Kinetics of infection and spread in H9
T-cells. The amounts of newly generated virions released in the culture
media at the days p.i. given (x-axis) were quantitated by ELISA for CA
(y-axis). m = pNL-Wt; d = pNL-Wt (vpu-); r = pNL-Epo-SP;
j = pNL-tPA-SP.pletely infected, as conﬁrmed by immunoﬂuorescence with
anti-HIV antibodies (not shown), but with a delay of about
2–3 days. These detrimental eﬀects of the SP exchanges on
virus infectivity may be the result of reduced Env incorpora-
tion into particles, as has been shown to be the case with
pNL-tPA-SP (Fig. 1B), of impaired Env functionality and/or,
alternatively, to cis eﬀects resulting from the nucleotide
exchanges within the proviral genome sequence.
3.3. Fusion activities of Env proteins with heterologous SPs
We next analysed the eﬀects of the SP exchanges on cell–cell
fusion activities mediated by the respective Env proteins. 293T
cells transfected with pNL-Wt, pNL-Wt (vpu-), pNL-Epo-SP
or pNL-tPA-SP were cocultivated with 1G5 cells, which are
Jurkat T-cells containing a stably integrated HIV-LTR lucifer-
ase construct. On fusion between these two cell types, HIV-Tat
protein expressed in the 293T cells activates luciferase expres-
sion from the LTR. The levels of luciferase activities measured
reﬂect the extents of cell–cell fusion induced by the respective
Envs. As a control for possible transactivation induced by se-
creted Tat or by possible spontaneous fusion, control incuba-
tions between transfected 293T cells and 1G5 cells were carried
out in the presence of CD4 antibodies which inhibit Env-med-
iated fusion. These luciferase values, which were however low,
were subtracted from the values obtained in the absence of
CD4 antibodies. As can be seen in Fig. 3, the levels of fusion
induced by expression of the Env proteins with Epo-SP or
tPA-SP were reduced to about 40% of that induced by expres-
sion of Wt-Env. This indicates that the SP exchanges have re-
sulted in impaired Env transport to the cell surface and/or to
impaired Env-function, phenomena which cannot be distin-
guished in this assay.
3.4. Infectivities mediated by VSV-G pseudotyped virions
We ﬁnally analysed if, in addition to possible eﬀects on Env
transport or functionality, the SP sequence exchanges within
the pNL-Epo-SP and pNL-tPA-SP genomes were themselves
contributing to the diminished infectivities of the respective




















Fig. 3. Cell–cell fusion activities. Luciferase activities in lysates of
cocultures of transfected 293T cells plus Jurkat 1G5 cells, reﬂecting the
extents of the respective Env-mediated cell–cell fusion activities, were
measured. The relative light units (RLU) measured for pNL-Wt (in the
range of 1–4 · 105 RLU per coculture) were set at 100% and the
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Fig. 4. Infectivities of VSV-G pseudotyped virions. ‘‘Single-round’’
infectivities were measured on Tzm-bl indicator cells in the presence of
antibodies to CD4. The titers for VSV-G pseudotyped pNL-Wt (which
were in the range of 1 · 106 IU/ml) were taken as 100% and the relative
infectivities of the mutant viruses calculated. The average of two
experiments is shown.
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virions on Tzm-bl cells were carried out in the presence of
antibodies against CD4 which we demonstrated to inhibit
HIV-Env-mediated infectivity to over 99% (data not shown).
As can be seen in Fig. 4, when infection was mediated by the
pseudotyping VSV-G protein, the infectivities of both pNL-
Epo-SP and pNL-tPA-SP virions were only very slightly re-
duced in comparison to pNL-Wt (vpu-). This would mean that
the more prominent reduction in infectivity seen with the
unpseudotyped virions (Fig. 2A) is largely mediated by Env-re-
lated phenomena and is inﬂuenced only to a minor extent, if at
all, in cis by the genome sequence exchanges themselves.
In summary, these results do not lend support for the use of
heterologous SPs in HIV-Env plasmids expressing wild-type
membrane-bound Env.
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